Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 292Unknown 69Terminated 49Recruiting 26Active not recruiting 21Withdrawn 14Not yet recruiting 12Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 2Lung Neoplasms 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Neoplasms 1NSCLC 1Mesothelioma 1Breast Neoplasms 1

Interventions

Trastuzumab 2Taxes 2Paclitaxel 2Fluorouracil 2Cyclophosphamide 2trastuzumab biosimilar HLX02 1tivozanib 1taletrectinib 1palbociclib 1eribulin 1atezolizumab 1Tomography, Optical Coherence 1Testosterone Propionate 1Testosterone 1Tamoxifen 1Tablets 1Specimen Handling 1Receptors, Chimeric Antigen 1Radiotherapy 1PF-05280014 1Ontruzant 1Ogivri 1Neoadjuvant Therapy 1Methotrexate 1Mastectomy, Segmental 1Lisaftoclax 1Interpersonal Psychotherapy 1Interleukin-2 1Injections 1G(M1) Ganglioside 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Breast Neoplasms × Docetaxel × Clear all
NCT02897050 2022-04-20

Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Suspended
170 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡